Chronic Lymphocytic Leukemia — A Phase I/II Study of GX15-070MS in Untreated CLL
Citation(s)
A Multi-Center, Open-Label, Phase I/II Study of Single-Agent GX15-070MS Administered Every 2 to 3 Weeks to Patients With Previously-Treated Chronic Lymphocytic Leukemia (CLL)